Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma

Christina Hackl, Peter Neumann, Michael Gerken, Martin Loss, Monika Klinkhammer-Schalke, Hans J Schlitt, Christina Hackl, Peter Neumann, Michael Gerken, Martin Loss, Monika Klinkhammer-Schalke, Hans J Schlitt

Abstract

Background: Purpose of this study was to analyse the surgical management and long-term clinical outcome of patients diagnosed with colorectal liver metastases (CLM) over a period of 10 years using data from a German tumour registry.

Methods: Retrospective analysis of 5772 patients diagnosed with colorectal adenocarcinoma between 2002 and 2007. Follow-up was continued until 2012.

Results: 1426 patients (24.7%) had CLM; 1019 patients (71%) had synchronous, 407 patients (29%) developed metachronous CLM. Hepatic resection was performed in 374 of the 1426 CLM patients (26%). A significant increase in liver resection rate from 16.6% for the 2002 cohort to 32% in later cohorts was observed. In centers specialized in liver surgery, CLM resection rates reached 46.6%. However, up to 52% of patients diagnosed with three or less CLM did not undergo liver surgery, although, if resected, patients with 1 CLM show a similar long-time survival as CRC patients who do not develop any CLM. Univariate and multivariate analyses adjusted for age, sex, year of resection, time of CLM diagnosis and number of CLM revealed a significant survival benefit for CLM resection (HR =0.355; CI 0.305-0.414). Furthermore, significant impact on OS was seen for age at diagnosis, perioperative chemotherapy and number of CLM.

Conclusions: We here present the first long-term, population-based analysis of the surgical management of CLM in Germany. Significant increase in hepatic resection rates, translating to a significant benefit in OS, was seen over years. However, we still see a striking potential for further improvements in interdisciplinary CLM management.

Figures

Figure 1
Figure 1
Synopsis of patients analysed in the present study. A total of 5772 patients diagnosed with colorectal cancer (CRC) in the years 2002–2007 were included. Of these, 1426 patients developed hepatic metastases and 374 underwent hepatic resection.
Figure 2
Figure 2
Incidence of colorectal cancer in the study population. A Relative (left axis) and absolute numbers (right axis, black line) of colorectal cancer patients with no (chequered), and metachronous (grey), synchronous (hatched) colorectal liver metastases by year of CRC diagnosis. B Relative cumulative incidence of colorectal liver metastases in months after diagnosis of the primary tumour.
Figure 3
Figure 3
Resection rates of colorectal liver metastases. A Resection rate of colorectal liver metastases (CLM) in % by year of CLM diagnosis. B Resection rate of CLM by year of CLM diagnosis in a subgroup of patients diagnosed with 1–3 CLM. C Resection rate of CLM by treatment centre: 2 academic liver centres compared with 28 regional hospitals.
Figure 4
Figure 4
Ten year overall survival analyses. A Comparison of 10-year OS in colorectal cancer cases with (n = 1426) an without (n = 4346) liver metastases (CLM) 2002–2007. B Comparison of 10-year OS in colorectal cancer liver metastases (CLM) patients by number of CLM independent of CLM resection. (1CLM: n = 236; 2-3CLM: n = 147; >3CLM: n = 729; unknown number of CLM: n = 314). C Comparison of 10-year OS in colorectal cancer liver metastases (CLM) patients with (n = 374) and without (n = 1052) curative liver resection.
Figure 5
Figure 5
Ten year overall survival analyses in patients undergoing hepatic resection. A Comparison of 10-year OS - Liver resection yes (n = 124) versus no (n = 112) in patients with singular metastasis. B Comparison of 10-year OS - Liver resection yes (n = 76) versus no (n = 71) in patients with 2–3 metastases. C Comparison of 10-year OS - Liver resection yes (n = 94) versus no (n = 635) in patients with more than 3 metastases. D Comparison of 10-year OS - Liver resection yes (n = 80) versus no (n = 234) in patients with unknown (x CLM) number of metastases.

References

    1. Van Cutsem E, Nordlinger B, Cervantes A, Group EGW Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol. 2010;21(Suppl 5):v93–97. doi: 10.1093/annonc/mdq222.
    1. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29(8):1083–1090. doi: 10.1200/JCO.2010.32.6132.
    1. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M, European Colorectal Metastases Treatment G, Sixth International Colorectal Liver Metastases W Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20(6):985–992. doi: 10.1093/annonc/mdn735.
    1. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–1280. doi: 10.1245/s10434-006-9045-5.
    1. Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, Taylor BR, Langer B, Gallinger S, Wei AC. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg. 2006;202(3):468–475. doi: 10.1016/j.jamcollsurg.2005.11.008.
    1. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13(5):668–676. doi: 10.1245/ASO.2006.05.039.
    1. Hackl C, Gerken M, Loss M, Klinkhammer-Schalke M, Piso P, Schlitt HJ. A population-based analysis on the rate and surgical management of colorectal liver metastases in Southern Germany. Int J Color Dis. 2011;26(11):1475–1481. doi: 10.1007/s00384-011-1278-5.
    1. Sjovall A, Jarv V, Blomqvist L, Singnomklao T, Cedermark B, Glimelius B, Holm T. The potential for improved outcome in patients with hepatic metastases from colon cancer: a population-based study. Eur J Surg Oncol. 2004;30(8):834–841. doi: 10.1016/j.ejso.2004.06.010.
    1. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93(4):465–474. doi: 10.1002/bjs.5278.
    1. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–259. doi: 10.1097/.
    1. Mantke R, Niepmann D, Gastinger I, Lippert H, Koch K, Quehl A. Hepatic resections. Analysis of data from the Tumor Documentation Center in the state of Brandenburg, Germany, focusing on liver metastases of colorectal carcinoma. Der Chirurg Zeitschrift fur alle Gebiete der operativen Medizen. 2006;77(12):1135–1143. doi: 10.1007/s00104-006-1247-7.
    1. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007;109(4):718–726. doi: 10.1002/cncr.22448.
    1. Morris EJ, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, Cottier B, Poston G. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg. 2010;97(7):1110–1118. doi: 10.1002/bjs.7032.
    1. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–4580. doi: 10.1200/JCO.2007.11.0833.
    1. Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T, Schlag PM, Punt CJ, Ledermann J, Ruers TJ. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer. 2014;50(5):912–919. doi: 10.1016/j.ejca.2013.12.008.
    1. Jegatheeswaran S, Mason JM, Hancock HC, Siriwardena AK. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg. 2013;148(4):385–391. doi: 10.1001/jamasurg.2013.1216.
    1. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48(10):1466–1475. doi: 10.1016/j.ejca.2012.02.057.
    1. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47. doi: 10.1016/S1470-2045(09)70330-4.
    1. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G, Gruppo Oncologico Nord O Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–1676. doi: 10.1200/JCO.2006.09.0928.
    1. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11(9):845–852. doi: 10.1016/S1470-2045(10)70175-3.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe